Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Evan Merrill

Podiatrist, Foot Surgery Medford, OR Doctor of Podiatric Medicine

NPI 1528166485 CMS profile 159569

1904 E Barnett Rd, Medford, OR 97504

Open in the dashboard

General payments

$15,663

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evan Merrill of Medford, OR is reported in the CMS Open Payments database as having received $15,663 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,358 11
2024 General $7,881 21
2023 General $1,316 10
2022 General $1,748 13
2021 General $3,155 16
2020 General $125 8
2019 General $78 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evan Merrill
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Evan Merrill were reported at $1,358. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Evan Merrill Podiatrist, Foot Surgery median Middle half National median
2019 $78 $167 $67–$484 $163
2020 $125 $114 $40–$323 $114
2021 $3,155 $171 $57–$502 $132
2022 $1,748 $196 $66–$556 $149
2023 $1,316 $187 $78–$466 $160
2024 $7,881 $190 $78–$557 $164
2025 $1,358 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $14,794 57 payments
  2. Stryker Corporation $237 5 payments
  3. Paratek Pharmaceuticals, Inc. $211 1 payment
  4. Integra LifeSciences Corporation $69 1 payment
  5. MIMEDX Group, Inc. $66 3 payments
  6. Djo, LLC $49 3 payments
  7. Merck Sharp & Dohme Corporation $48 3 payments
  8. Smith+Nephew, Inc. $33 2 payments
  9. Wright Medical Technology, Inc. $32 1 payment
  10. Organogenesis Inc. $26 1 payment
  11. Other $98 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $7,126 24 payments
  2. Consulting Fee $5,390 2 payments
  3. Food and Beverage $3,134 57 payments
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM Foot And Ankle $10,797 38 payments
  2. Lapiplasty System Y $2,915 13 payments
  3. LAPIPLASTY $798 1 payment
  4. NUZYRA $211 1 payment
  5. AUGMENT INJECTABLE $146 1 payment
  6. CITREFIX $146 1 payment
  7. Integra Recon-Skin And Wound $69 1 payment
  8. Integra Recon-Skin And Wound $69 1 payment
  9. Integra Recon-Skin And Wound $69 1 payment
  10. INTEGRA DERMAL REGENERATION TEMPLATE $69 1 payment
  11. Other $602 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

318

Median for Podiatry: 160

Drug cost

$4,352

Median for Podiatry: $2,368

Branded share of claims

31.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 136 $1,373
Pregabalin Generic 17 $1,129
Terbinafine Hcl Generic 52 $951
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 51 $541
Doxycycline Monohydrate Generic 14 $137
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $124
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 29 $98

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$102,736

Of which drugs: $5,682

Medicare patients

464

Average age 76

Services billed

1,831

258 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 60%
Diabetes 46%
Chronic kidney disease 29%
Depression 26%
Atrial fibrillation 22%
Heart failure 21%
Ischemic heart disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 27 46 $224

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record